Literature DB >> 12039955

Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication.

Joao Goncalves1, Frederico Silva, Acilino Freitas-Vieira, Mariana Santa-Marta, Rui Malhó, Xiaoyu Yang, Dana Gabuzda, Carlos Barbas.   

Abstract

Human immunodeficiency virus type 1 (HIV-1)-encoded Vif protein is important for viral replication and infectivity. Vif is a cytoplasmic protein that acts during virus assembly by an unknown mechanism, enhancing viral infectivity. The action of Vif in producer cells is essential for the completion of proviral DNA synthesis following virus entry. Therefore, Vif is considered to be an important alternative therapeutic target for inhibition of viral infectivity at the level of viral assembly and reverse transcription. To gain insight into this process, we developed a Vif-specific single-chain antibody and expressed it intracellularly in the cytoplasm. This intrabody efficiently bound Vif protein and neutralized its infectivity-enhancing function. Intrabody-expressing cells were shown to be highly refractory to challenge with different strains of HIV-1 and HIV-1-infected cells. Inhibition of Vif by intrabody expression in the donor cell produced viral particles that do not complete reverse transcription in the recipient cell. The anti-Vif scFv was shown to be specific for Vif protein because its function was observed only in nonpermissive cells (H9, CEM, and U38). Moreover, transduction of peripheral blood mononuclear cells with an HIV-derived retroviral vector expressing Vif intrabody was shown to confer resistance to laboratory-adapted and primary HIV strains. This study provides biochemical evidence for the role of Vif in the HIV-1 lifecycle and validates Vif as a target for the control of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039955     DOI: 10.1074/jbc.M201906200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

Review 2.  The production and application of single-chain antibody fragments.

Authors:  D Blazek; V Celer
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

3.  Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.

Authors:  Sofia Corte-Real; Chris Collins; Frederico Aires da Silva; J Pedro Simas; Carlos F Barbas; Yuan Chang; Patrick Moore; Joao Goncalves
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

Review 4.  Understanding helicases as a means of virus control.

Authors:  D N Frick; A M I Lam
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 5.  Antibodies against G-protein coupled receptors: novel uses in screening and drug development.

Authors:  Achla Gupta; Andrea S Heimann; Ivone Gomes; Lakshmi A Devi
Journal:  Comb Chem High Throughput Screen       Date:  2008-07       Impact factor: 1.339

6.  Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin.

Authors:  Juliane Karthe; Kathi Tessmann; Jisu Li; Raiki Machida; Maaike Daleman; Dieter Häussinger; Tobias Heintges
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

7.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Authors:  Tao Zuo; Donglai Liu; Wei Lv; Xiaodan Wang; Jiawen Wang; Mingyu Lv; Wenlin Huang; Jiaxin Wu; Haihong Zhang; Hongwei Jin; Liangren Zhang; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

8.  Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication.

Authors:  Frederico Aires da Silva; Min Li; Sylvie Rato; Sara Maia; Rui Malhó; Kylie Warren; David Harrich; Robert Craigie; Carlos Barbas; Joao Goncalves
Journal:  Biotechnol Appl Biochem       Date:  2012-10-10       Impact factor: 2.431

9.  Functional domain organization of human APOBEC3G.

Authors:  Barry D Gooch; Bryan R Cullen
Journal:  Virology       Date:  2008-07-18       Impact factor: 3.616

Review 10.  The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.

Authors:  David N Frick
Journal:  Curr Issues Mol Biol       Date:  2007-01       Impact factor: 2.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.